The trial is carried out in collaboration with Presidio Pharmaceuticals cialis pas cher.

Boehringer Ingelheim completes individual enrolment for interferon-free of charge hepatitis C treatment Boehringer Ingelheim today announced the completion of individual enrolment for a Stage IIa clinical trial investigating a fresh interferon-free, all-oral, direct-performing antiviral mixture treatment for individuals with genotype-1a chronic hepatitis C virus contamination cialis pas cher read more . The trial is carried out in collaboration with Presidio Pharmaceuticals, Inc. The principal endpoint of the trial can be sustained virologic response 12 weeks after treatment can be completed . Both businesses will retain all privileges with their respective compounds. Presidio provides operational responsibility because of this collaborative trial, with oversight by an intercompany task team.

prix

For the arriving five years, we plan, nevertheless, to renew our product sales drivers markedly,’ stated von Baumbach. ‘Our successes in analysis and development will be the drivers of the.’ With net product sales of over 1.4 billion euros, business in Customer HEALTHCARE medicines accounted for 11 percent of the group’s net product sales.5 percent in euro terms). Boehringer Ingelheim generated net product sales of 501 million euros in 2014 with the agreement making of biopharmaceuticals. USA, Japan and Germany will be the top three sales marketplaces The three most significant markets – USA, Japan and Germany – accounted for about 55 percent of Boehringer Ingelheim’s total net product sales in 2014, with net sales of around 912 million euros generated in Germany, net product sales of around 1.7 billion euros in Japan and around 4.6 billion euros in america.